Literature DB >> 29344027

Plasma Volume and Renal Function Predict Six-Month Survival after Hospitalization for Acute Decompensated Heart Failure.

Kenneth C Bilchick1, Nathaniel Chishinga1, Alex M Parker1, David X Zhuo1, Mitchell H Rosner2, LaVone A Smith1, Hunter Mwansa3, Jacob N Blackwell1, Peter A McCullough4, Sula Mazimba1.   

Abstract

BACKGROUND: Plasma volume (PV) is contracted in stable patients with heart failure (HF) due to decongestion strategies. On the other hand, increased PV can adversely affect the trajectory of HF. We therefore examined the effects of increased percentage change in PV (%ΔPV), blood urea nitrogen (BUN), and %ΔPV stratified by BUN and glomerular filtration rate (GFR) on survival after discharge in patients hospitalized for acute decompensated HF (ADHF).
METHODS: We used the Strauss-Davis-Rosenbaum formula to calculate the %ΔPV between baseline and hospital discharge in a cohort from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness trial (ESCAPE). Kaplan-Meier curves were constructed for survival over 6 months. Cox proportional hazards regression was used to obtain adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) for the associations between survival after discharge and %ΔPV, BUN, and %ΔPV stratified by BUN and GFR.
RESULTS: Of the 324 patients included in our study (age 56.1 ± 13.6 years, 26.5% female), those with increased or no %ΔPV at discharge were less likely to survive at 6 months compared with those having reduced %ΔPV (log rank, p = 0.0093). Increased %ΔPV (HR 1.08 per 10% increase; 95% CI: 1.02-1.14) and increased BUN at discharge (HR 1.02 per mg/dL; 95% CI: 1.01-1.03) were independently associated with worse survival. Decreasing %ΔPV had a greater association with improved survival in patients with discharge BUN <31 mg/dL (p = 0.02) and discharge GFR >40 mL/min/1.73 m2 (p = 0.047).
CONCLUSIONS: Increased %ΔPV and BUN at discharge predicted worse 6-month survival in patients with ADHF. Decreased %ΔPV with low BUN or high GFR at discharge was associated with improved survival.

Entities:  

Keywords:  Heart failure; Mortality; Plasma volume

Year:  2017        PMID: 29344027      PMCID: PMC5757574          DOI: 10.1159/000481149

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  30 in total

1.  Clinical correlates of hemoconcentration during hospitalization for acute decompensated heart failure.

Authors:  Carlos Davila; Alex Reyentovich; Stuart D Katz
Journal:  J Card Fail       Date:  2011-09-03       Impact factor: 5.712

2.  Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.

Authors:  Cynthia Binanay; Robert M Califf; Vic Hasselblad; Christopher M O'Connor; Monica R Shah; George Sopko; Lynne W Stevenson; Gary S Francis; Carl V Leier; Leslie W Miller
Journal:  JAMA       Date:  2005-10-05       Impact factor: 56.272

Review 3.  Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition.

Authors:  M Packer
Journal:  Eur Heart J       Date:  1990-05       Impact factor: 29.983

4.  Hypervolemia is associated with increased mortality among hemodialysis patients.

Authors:  Rajiv Agarwal
Journal:  Hypertension       Date:  2010-07-12       Impact factor: 10.190

5.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.

Authors:  Tamara B Horwich; Gregg C Fonarow; Michele A Hamilton; W Robb MacLellan; Jeff Borenstein
Journal:  J Am Coll Cardiol       Date:  2002-06-05       Impact factor: 24.094

6.  Intravenous administration of furosemide in heart failure.

Authors:  M Davidov; N Kakaviatos; F A Finnerty
Journal:  JAMA       Date:  1967-06-05       Impact factor: 56.272

7.  Hemodilution is common in patients with advanced heart failure.

Authors:  Ana-Silvia Androne; Stuart D Katz; Lars Lund; John LaManca; Alhakam Hudaihed; Katarzyna Hryniewicz; Donna M Mancini
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

8.  Plasma Volume Is Normal but Heterogeneously Distributed, and True Anemia Is Highly Prevalent in Patients With Stable Heart Failure.

Authors:  Petra Nijst; Frederik H Verbrugge; Philippe B Bertrand; Pieter Martens; Matthias Dupont; Olivier Drieskens; Joris Penders; W H Wilson Tang; Wilfried Mullens
Journal:  J Card Fail       Date:  2016-08-22       Impact factor: 5.712

9.  Blood volume following diuresis induced by furosemide.

Authors:  C J Schuster; M H Weil; J Besso; M Carpio; R J Henning
Journal:  Am J Med       Date:  1984-04       Impact factor: 4.965

10.  Prognostic Value of Estimated Plasma Volume in Heart Failure.

Authors:  Kévin Duarte; Jean-Marie Monnez; Eliane Albuisson; Bertram Pitt; Faiez Zannad; Patrick Rossignol
Journal:  JACC Heart Fail       Date:  2015-11       Impact factor: 12.035

View more
  3 in total

1.  Diagnostic and prognostic value of plasma volume status at emergency department admission in dyspneic patients: results from the PARADISE cohort.

Authors:  Tahar Chouihed; Patrick Rossignol; Adrien Bassand; Kévin Duarte; Masatake Kobayashi; Déborah Jaeger; Sonia Sadoune; Aurélien Buessler; Lionel Nace; Gaetan Giacomin; Thibaut Hutter; Françoise Barbé; Sylvain Salignac; Nicolas Jay; Faiez Zannad; Nicolas Girerd
Journal:  Clin Res Cardiol       Date:  2018-10-28       Impact factor: 5.460

Review 2.  Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?

Authors:  Agata Bielecka-Dabrowa; Breno Godoy; Joerg C Schefold; Michael Koziolek; Maciej Banach; Stephan von Haehling
Journal:  Curr Heart Fail Rep       Date:  2018-08

Review 3.  Estimated plasma volume status in heart failure: clinical implications and future directions.

Authors:  Masatake Kobayashi; Nicolas Girerd; Kevin Duarte; Tahar Chouihed; Taishiro Chikamori; Bertram Pitt; Faiez Zannad; Patrick Rossignol
Journal:  Clin Res Cardiol       Date:  2021-01-06       Impact factor: 5.460

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.